Back to results
US 6,638,942 B1Granted
Spiro-indolines as Y5 receptor antagonists
AssigneesMerck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
InventorsYing-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
Life of this patent
Estimating the term…
Abstract
Compounds of general structural formula I are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
Claims13
A compound of structural formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- V and W are independently selected from CH and N, provided that V and W cannot simultaneously be CH and that V and W cannot simultaneously be N;
- R1 is H, C1-3 alkyl, C1-3 alkoxy, F, or Cl;
- R2 is S(O)n R6, COR6 or CHO, wherein
- n is 0, 1 or 2, and
- R6 is N(R3)2 or C1-3 alkyl;
- R3 is independently H or C1-3 alkyl;
- Ar is aryl or heteroaryl;
- R4 and R5 are independently selected from:
- (1) hydrogen,
- (2) aryl, either unsubstituted or substituted with
- (a) halo,
- (b) C1-3 alkoxy,
- (c)-N(C1-3 alkyl)2,
- (d) C2-4 alkanoyl, or
- (e) aryl,
- (3) nitro,
- (4) C1-5 alkyl,
- (5) C1-5 alkoxy,
- (6) hydroxy-C1-3 alkyl,
- (7) carboxy,
- (8) halo,
- (9) C1-5 alkylthio,
- (10) C1-5 ethoxycarbonyl,
- (11) pyridylcarbonyl,
- (12) benzoyl,
- (13) phenyl-C1-3 alkoxy,
- (14) pyridyl, either unsubstituted or substituted with C1-3 alkyl or C1-3 alkoxy,
- (15) C3-6 cycloalkyl,
- (16) oxazolyl,
- (17) thiazolyl,
- (18) triazolyl,
- (19) phenoxy, and
- (20) C2-6 alkanoyl.
31 more elements
Dependencies are inferred from the claim text.